首页|Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19
Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NSTL
Elsevier
On March 11， 2020 the World Health Organization (WHO) declared the state of global pandemic caused by the new SARS-CoV-2 (COVID-19)。 To date， no antivirals directed against SARS-CoV-2 or effective vaccines to combat the viral infection are available。 Severe acute respiratory syndrome caused by SARS-CoV-2 is treated empirically with antivirals， anti-inflammatory， anticoagulants。 The approval of an effective vaccine still takes time。 In this state， it may be useful to find new therapeutic solutions from drugs already on the market。 Recent hypotheses suggest that the use of AT-1 receptor antagonists (ARB) in combination with neprilisin inhibitors (NEPi) could indirectly provide clinical benefits to patients with SARS-CoV-2 and cardiac involvement。 In this article we investigate and describe a possible innovative pharmacological approach for the treatment of the most severe stages of COVID-19 infection。
NSTL
Elsevier
